Patritumab Deruxtecan in EGFR-mutated NSCLC post EGFR TKI and Chemotherapy Physician's Weekly, 19 Sep 2023 Bookmark 1. The objective response rate was 29.8% (1% complete response, 66% partial response) with a PFS of 5.5 months and a…